<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="79839"><DrugName>interferon alfa-2b biosimilar, Virchow</DrugName><DrugNamesKey><Name id="42758618">interferon alfa-2b</Name></DrugNamesKey><DrugSynonyms><Name><Value>interferon alfa-2b</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>interferon alfa-2b biosimilar, Virchow</Value></Name><Name><Value>interferon alpha-2b</Value></Name></DrugSynonyms><CompanyOriginator id="1048090">Virchow Group</CompanyOriginator><CompaniesPrimary><Company id="1048090">Virchow Group</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1048090" type="Company"><TargetEntity id="4297930809" type="organizationId">Virchow Group</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"/><TargetEntity id="D019694" type="MeSH"/><TargetEntity id="-1284790527" type="omicsDisease"/><TargetEntity id="429" type="siCondition"/></SourceEntity><SourceEntity id="153" type="ciIndication"><TargetEntity id="10019744" type="MEDDRA"/><TargetEntity id="D019698" type="MeSH"/><TargetEntity id="-776640207" type="omicsDisease"/><TargetEntity id="430" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00973" type="ciTarget"><TargetEntity id="155743165834403" type="siTarget">Interferon alpha-2</TargetEntity><TargetEntity id="-269142832" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hepatitis B virus infection - India - Aug-2012</FirstLaunched><FirstLaunched>Hepatitis C virus infection - India - Aug-2012</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="152">Hepatitis B virus infection</Indication><Indication id="153">Hepatitis C virus infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="214">Interferon alpha 2 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="898">Formulation powder</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="962">Biosimilar product</Technology><Technology id="750">Freeze drying</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2012-10-22T09:52:49.000Z</LastModificationDate><ChangeDateLast>2012-10-08T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-02T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1048090"&gt;Virchow Group&lt;/ulink&gt; has developed and launched an &lt;ulink linkType="Drug" linkID="18187"&gt;interferon alfa-2b&lt;/ulink&gt; biosimilar for the treatment of HBV and HCV infections. By August 2012, the biosimilar had been launched [&lt;ulink linkType="Reference" linkID="1312295"&gt;1312295&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1048090">Virchow Group</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1312295" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1048090">Virchow Group</Company><Country id="IN">India</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="153">Hepatitis C virus infection</Indication><StatusDate>2012-08-01T00:00:00.000Z</StatusDate><Source id="1312295" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-00973"><Name>Interferon alpha 2 ligand</Name><SwissprotNumbers><Swissprot>P01563</Swissprot><Swissprot>P01573</Swissprot><Swissprot>P05004</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2135410" number="WO-2005077973" title="Purification of recombinant human proteins"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Virchow Group" id="1048090"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Reddy's Laboratories Ltd" id="29387"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>